Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Edgestream Partners L.P.

Edgestream Partners L.P. decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 51.3% during the 1st quarter, Holdings Channel.com reports. The fund owned 3,263 shares of the pharmaceutical company’s stock after selling 3,440 shares during the period. Edgestream Partners L.P.’s holdings in Vertex Pharmaceuticals were worth $1,457,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Kentucky Retirement Systems lifted its position in shares of Vertex Pharmaceuticals by 19.5% during the first quarter. Kentucky Retirement Systems now owns 19,299 shares of the pharmaceutical company’s stock worth $8,618,000 after purchasing an additional 3,152 shares in the last quarter. Tri Locum Partners LP purchased a new stake in Vertex Pharmaceuticals during the 1st quarter worth approximately $57,744,000. Ashton Thomas Securities LLC increased its stake in Vertex Pharmaceuticals by 5.0% during the 1st quarter. Ashton Thomas Securities LLC now owns 3,048 shares of the pharmaceutical company’s stock worth $1,361,000 after buying an additional 146 shares during the period. Smith Group Asset Management LLC lifted its holdings in Vertex Pharmaceuticals by 7.1% during the 1st quarter. Smith Group Asset Management LLC now owns 55,746 shares of the pharmaceutical company’s stock worth $24,893,000 after buying an additional 3,695 shares in the last quarter. Finally, ADAR1 Capital Management LLC lifted its holdings in Vertex Pharmaceuticals by 9.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 15,075 shares of the pharmaceutical company’s stock worth $6,732,000 after buying an additional 1,359 shares in the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Trading Down 1.3%

Shares of VRTX opened at $470.72 on Tuesday. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $533.67. The firm’s fifty day simple moving average is $471.34 and its 200-day simple moving average is $460.44. The firm has a market capitalization of $119.47 billion, a price-to-earnings ratio of 27.92, a PEG ratio of 2.15 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01). The firm had revenue of $3.33 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.Vertex Pharmaceuticals’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same period last year, the firm posted $4.52 earnings per share. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post 17.01 earnings per share for the current fiscal year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Duncan Mckechnie sold 1,541 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total transaction of $799,779.00. Following the completion of the sale, the executive vice president directly owned 11,001 shares of the company’s stock, valued at $5,709,519. The trade was a 12.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $524.99, for a total value of $787,485.00. Following the transaction, the executive vice president directly owned 45,321 shares of the company’s stock, valued at approximately $23,793,071.79. This represents a 3.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 17,452 shares of company stock worth $8,103,997 over the last ninety days. Corporate insiders own 0.20% of the company’s stock.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue rose 12.5% year over year to approximately $3.33 billion, exceeding Wall Street expectations. Growth was supported by continued demand for Vertex’s cystic fibrosis medicines, as well as contributions from sickle-cell disease, beta thalassemia and acute-pain treatments. Vertex Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Vertex raised its full-year 2026 revenue outlook to $13.1 billion-$13.2 billion, above the roughly $13.0 billion analyst consensus. The higher forecast reflects sustained strength in cystic fibrosis drug sales. Vertex raises annual revenue forecast
• Positive Sentiment: Profitability remained strong, with a 35.5% net margin and operating cash flow of approximately $1.4 billion. Vertex also highlighted strong growth from CASGEVY, its gene-edited therapy developed with CRISPR Therapeutics, and its expanding non-cystic-fibrosis pipeline.
• Neutral Sentiment: Vertex announced an agreement to acquire Crinetics Pharmaceuticals for approximately $10.0 billion in equity value, or about $8.8 billion net of estimated cash. The transaction would add PALSONIFY (paltusotine) and establish rare endocrine diseases as another major business area, but its scale may increase near-term execution and valuation risk. Crinetics acquisition announcement
• Negative Sentiment: Adjusted EPS was $4.73, narrowly below the $4.74 consensus; another data provider cited a $4.79 estimate. The modest miss likely drove the negative reaction despite revenue outperforming expectations and EPS increasing from $4.52 a year earlier. Vertex Pharmaceuticals Q2 Earnings Lag Estimates

Analyst Upgrades and Downgrades

Several brokerages have commented on VRTX. UBS Group raised their price target on shares of Vertex Pharmaceuticals from $545.00 to $585.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Wall Street Zen lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, June 28th. Weiss Ratings upgraded Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, July 17th. Barclays lifted their target price on Vertex Pharmaceuticals from $607.00 to $615.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Finally, Morgan Stanley boosted their target price on Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 5th. Twenty-two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $559.61.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.